antimicrobi
peptid
current
consid
promis
antivir
compound
current
assay
evalu
effect
peptid
envelop
virus
base
liposom
hemolysi
encumb
artifici
natur
liposom
distinct
membran
composit
use
erythrocyt
propos
novel
assay
system
base
enzymat
ebola
viruslik
particl
contain
sensit
luciferas
report
assay
valid
sever
cation
anion
peptid
compar
lentiviru
inactiv
hemolyt
assay
assay
sensit
easi
perform
standard
biosafeti
level
laboratori
potenti
highthroughput
screen
use
viruslik
particl
assay
provid
system
close
relat
nativ
virus
possibl
elimin
issu
associ
artifici
set
up
identifi
camw
kwklwkkiekwgqgigavlkwlttwl
peptid
greatest
antivir
activ
infecti
lentivir
vector
filovir
viruslik
particl
antimicrobi
peptid
amp
found
major
live
organ
involv
primari
defens
mechan
bacteria
fungi
potenti
hazard
pathogen
amp
found
secret
invertebr
venom
intracellular
space
one
exampl
secret
peptid
bombesin
secret
skin
european
firebelli
toad
bombina
bombina
anoth
peptid
secret
toad
maximin
bombina
maxima
plenti
antimicrobi
peptid
produc
variou
frog
speci
peptid
cathelicidin
found
among
mammal
locat
lysosom
macrophag
polymorphonuclear
leukocyt
play
critic
role
innat
immun
defens
peptid
substanti
compon
insect
toxin
melittin
present
honey
bee
api
mellifera
venom
mucroporin
scorpion
lycha
mucronatu
venom
andor
lycotoxin
wolf
spider
lycosa
carolinensi
venom
share
mechan
function
amp
format
pore
cell
membran
lead
loss
membran
potenti
ion
imbal
cell
death
due
membranolyt
properti
restrict
bacteria
effect
eukaryot
cell
peptid
test
potenti
anticanc
compound
mani
shown
strong
anticanc
effect
either
alon
conjug
tumor
target
tag
abil
specif
interact
cell
membran
caus
loss
membran
integr
led
investig
virolyt
viru
inhibitori
properti
amp
li
et
al
shown
activ
sever
envelop
virus
measl
sarscov
influenza
virus
hecat
mellitin
analog
shown
inhibit
herp
simplex
induc
cell
fusion
viru
spread
antivir
effect
necessarili
need
link
membran
lysi
shown
melittin
cecropin
peptid
suppress
viral
gene
express
micromolar
concentr
well
toxic
concentr
cell
http
suggest
mechan
unrel
membranolyt
properti
peptid
result
prompt
search
new
peptid
improv
antivir
antibacteri
activ
cytotox
lower
hemolyt
activ
etc
sever
approach
use
toward
goal
ration
redesign
exist
peptid
greatli
improv
desir
properti
silico
comput
led
construct
hecat
deriv
melittin
design
alter
surfac
charg
distribut
without
affect
amphipath
charact
altern
seri
mutat
introduc
parent
peptid
screen
biolog
assay
result
mutant
desir
properti
select
work
approach
appli
one
sheep
cathelicidin
anoth
viabl
approach
peptid
design
util
peptid
domain
swap
differ
peptid
cecropin
melittin
hybrid
construct
way
effect
hybrid
contain
ntermin
amino
acid
deriv
cecropin
connect
first
amino
acid
melittin
ca
hybrid
peptid
modifi
increas
proteolyt
stabil
enhanc
antimicrobi
potenc
replac
residu
tryptophan
reduc
hemolyt
activ
compar
parent
peptid
fourth
approach
compris
design
entir
synthet
peptid
cation
kala
peptid
synthes
agent
dna
oligonucleotid
deliveri
cell
highli
charg
repetit
amino
acid
motif
destabil
membran
bind
dna
high
affin
sequenti
homolog
kala
anion
peptid
gala
peptid
structur
homolog
kala
peptid
posit
charg
lysin
residu
replac
neg
charg
glutam
acid
peptid
design
interact
lipid
bilay
preferenti
acid
ph
late
endosom
despit
fact
mani
peptid
describ
virolyt
activ
never
comprehens
compar
one
reason
could
biosafeti
concern
experi
activ
virus
ebola
marburg
conduct
laboratori
strictli
control
biosafeti
environ
even
less
danger
virus
hiv
requir
special
laboratori
environ
train
staff
order
facilit
futur
research
aim
design
test
new
antivir
peptid
design
virolyt
assay
base
nontox
noninfecti
viruslik
particl
vlp
vlp
resembl
parent
virus
structur
usual
carri
structur
protein
necessari
viru
capsid
assembl
viru
envelop
membran
deriv
host
cell
viru
envelop
protein
necessari
recognit
cellular
receptor
henc
construct
vlp
imit
ebola
viru
express
structur
protein
actual
prerequisit
format
product
vlp
fluoresc
vlp
base
filovirus
describ
previous
martin
et
al
construct
fusion
protein
visual
vlp
dendrit
cell
fluoresc
marburg
viru
vlp
contain
red
fluoresc
protein
use
livecel
imag
marburg
virusinfect
cell
howev
aim
work
develop
simpl
system
quantifi
releas
viral
content
loss
membran
permeabl
caus
lytic
peptid
purpos
use
fluoresc
vlp
chose
approach
viral
membran
separ
enzym
activ
substrat
order
achiev
high
sensit
possibl
use
luciferas
report
fuse
structur
protein
ebola
viru
membran
poorli
permeabl
substrat
furimazin
attach
nanoluciferas
nluc
nterminu
ebola
protein
show
cell
transfect
plasmid
plasmid
code
viru
envelop
protein
produc
enzymat
vlp
enzym
encapsul
insid
particl
protect
lipid
envelop
make
poorli
access
substrat
nluc
substrat
newli
develop
coelenterazin
deriv
furimazin
optim
nluc
provid
brighter
fluoresc
greater
chemic
stabil
design
assay
evalu
membranolyt
pore
form
properti
peptid
reflect
activ
nluc
pretreat
vlp
peptid
assay
carri
sever
differ
peptid
sensit
reliabl
reflect
result
infecti
lentivir
vector
inactiv
use
easi
enzymat
screen
new
peptid
membran
destabil
drug
antivir
therapi
vlp
modifi
envelop
protein
broad
spectrum
virus
therefor
cytotox
peptid
select
target
inactiv
specif
highli
pathogen
virus
evalu
common
laboratori
without
regard
special
biosafeti
condit
peptid
synthes
solid
phase
cem
liberti
blue
peptid
synthes
matthew
nc
usa
fmoc
protect
precursor
puriti
peptid
evalu
use
hplcuv
esa
inc
chelmsford
usa
final
puriti
greater
molecular
weight
peptid
verifi
hplcesiqtof
bruker
daltonik
gmbh
bremen
germani
peptid
dissolv
distil
water
except
anion
peptid
maximin
gala
small
addit
sodium
hydroxid
necessari
dissolv
peptid
peptid
util
studi
basic
characterist
list
tabl
plasmid
express
construct
overlap
pcr
nluc
open
read
frame
orf
amplifi
pnanoluc
promega
madison
wi
usa
primer
nlfw
atatgctagcgccaccatggtcttcacactcgaagatttc
nlrv
aacccgcctcatggtggatccgccgctgccgcctccggagcccctaggcgccagaatgcgttcgcacagccg
revers
primer
introduc
flexibl
peptid
linker
gsgggsgg
ebola
protein
orf
amplifi
plasmid
bei
resourc
manassa
va
usa
primer
agcggcggatccaccatgaggcgggttatattgcctactgc
tatagaattcttacttctcaatcacagctggaagac
overlap
pcr
carri
mix
primari
pcr
product
primer
nlfw
proof
read
polymeras
phusion
new
england
biolab
ipswich
usa
use
pcr
result
pcr
product
cleav
nhei
ecori
clone
pcag
vector
plasmid
lentiviru
product
addgen
plasmid
prsvrev
addgen
plasmid
pmdlgprre
addgen
plasmid
gift
didier
trono
pcscsppwgfp
aka
pbobgfp
addgen
plasmid
gift
inder
verma
plasmid
express
marburg
viru
envelop
protein
purchas
bei
resourc
plasmid
code
hybrid
envelop
protein
fugc
contain
extracellular
part
rabi
viru
transmembran
intracellular
part
deriv
vesicular
stomat
viru
vsv
glycoprotein
gift
kazuto
kobayashi
hek
cell
cultiv
standard
cell
cultur
condit
media
supplement
bovin
calf
serum
penicillinstreptomycin
mix
viruslik
particl
produc
cell
transfect
cm
flask
g
polyethyleneimin
pei
g
ebov
g
plasmid
code
viru
envelop
protein
vsv
envelop
pcaggsmarv
gp
marburg
viru
envelop
ng
pmaxgfp
lonza
basel
switzerland
permit
fluoresc
control
transfect
effici
h
transfect
mix
remov
replac
vlp
collect
medium
optimem
gibco
waltham
usa
lentiviru
product
use
third
gener
lentivir
vector
improv
biosafeti
featur
transfect
hek
cell
seed
plate
transfect
confluenc
pei
dna
complex
cotransfect
mix
compris
pcscsppwgfp
prsvrev
pmdlgprre
plasmid
pfugc
code
hybrid
envelop
protein
pseudoco
lentivirus
produc
transfect
hek
cell
cm
flask
g
pei
g
prsvrev
g
pmdlgprre
g
pbobgfp
g
pfugc
transfect
mix
remov
h
later
replac
optimem
medium
viru
collect
virus
collect
twice
h
pool
togeth
sampl
centrifug
remov
detach
cell
cellular
debri
clear
supernat
use
infect
assay
human
blood
treat
edta
equin
blood
collect
heparin
tube
centrifug
min
ml
sediment
red
blood
cell
rbc
sever
time
wash
pb
centrifug
red
stain
supernat
visibl
erythrocyt
dilut
ml
phosphat
buffer
salin
pb
ph
select
peptid
dilut
l
pb
l
wash
rbc
ad
peptid
concentr
indic
graph
reflect
final
concentr
peptid
reaction
mix
l
cell
incub
c
one
hour
centrifug
l
supernat
transfer
wellplat
final
absorb
measur
nm
percentag
hemolysi
determin
follow
equat
hemolysi
ac
ac
absorb
supernat
sampl
incub
peptid
ac
absorb
supernat
neg
control
absorb
supernat
posit
control
triton
caus
complet
lysi
rbc
result
express
averag
three
replica
clear
supernat
l
lentivirus
code
egfp
coat
fugc
hybrid
envelop
protein
mix
individu
peptid
final
concentr
incub
c
h
l
fc
ad
hek
cell
seed
plate
night
cell
cultur
medium
replac
l
treat
viru
mix
medium
order
reduc
peptid
concentr
nontox
level
report
cell
estim
viru
concentr
correspond
moi
imag
gfpexpress
cell
taken
postinfect
cell
lyse
h
later
tb
buffer
contain
tween
gfp
fluoresc
measur
ex
nm
em
nm
gfp
fluoresc
relat
amount
protein
measur
absorb
nm
result
express
averag
three
replica
order
confirm
final
peptid
concentr
viru
prepar
kill
cell
treat
hek
cell
peptid
correspond
highest
concentr
dilut
peptid
h
perform
stain
gml
hoechst
cell
cultur
supernat
vlp
produc
cell
collect
centrifug
remov
cell
transfer
new
tube
l
clear
supernat
incub
l
concentr
stock
solut
peptid
c
min
commerci
avail
nluc
assay
buffer
contain
deterg
use
detergentfre
buffer
mm
kcl
mm
triscl
ph
mm
order
avoid
damag
viral
membran
deterg
luciferas
assay
carri
l
analyz
sampl
l
luciferas
assay
reagent
compos
nanoglo
luciferas
assay
substrat
promega
madison
wi
usa
detergentfre
buffer
ratio
control
use
vlp
treat
tween
luciferas
activ
sampl
treat
peptid
subtract
activ
sampl
treat
peptid
luciferas
activ
relat
activ
sampl
lyse
tween
result
express
averag
three
replica
cell
seed
plate
overnight
next
day
cell
cultur
medium
replac
fresh
medium
contain
variou
concentr
individu
peptid
cell
cultiv
h
effect
peptid
cell
viabil
analyz
mtt
assay
result
express
averag
four
replica
hemolyt
assay
carri
human
equin
rbc
show
cation
peptid
caus
substanti
releas
hemoglobin
rbc
though
differ
activ
fig
melittin
camw
highli
hemolyt
human
equin
rb
hand
anion
peptid
gala
maximin
virtual
hemolyt
activ
test
erythrocyt
kala
moder
hemolyt
activ
type
rbc
peptid
differ
abil
releas
hemoglobin
human
equin
rbss
hecat
two
peptid
moder
lyse
human
erythrocyt
virtual
effect
equin
rbc
gener
seem
hors
erythrocyt
less
sensit
peptidemedi
lysi
exampl
mellitin
concentra
tion
caus
lysi
approxim
human
rbc
equin
cell
lyse
viru
infect
assay
use
lentivirus
carri
gene
express
egfp
report
protein
infect
cell
viru
particl
produc
hybrid
rabi
vsv
envelop
protein
lead
highest
yield
infect
hek
report
cell
unpublish
observ
alreadi
h
infect
appar
differ
infect
viral
vector
treat
test
peptid
fig
profound
inhibitori
effect
trigger
melittin
camw
concentr
gfpexpress
cell
found
quantif
gfp
fluoresc
shown
fig
camw
exhibit
strong
inhibitori
effect
even
concentr
concentr
mani
virus
remain
infecti
melittin
treatment
substanti
antivir
effect
note
cation
peptid
hecat
kala
though
inhibit
becam
appar
concentr
peptid
least
inhibitori
peptid
surpris
differ
among
anion
peptid
maximin
small
effect
viru
infect
gala
peptid
behav
remark
potent
inhibitor
despit
fact
peptid
achiev
activ
conform
acid
ph
could
exclud
possibl
peptid
might
increas
viru
infect
multipl
infect
moi
chosen
measur
gfp
fluoresc
fig
reveal
maximin
kala
concentr
might
slightli
increas
amount
produc
gfp
increas
signific
order
exclud
possibl
peptid
present
dilut
lentiviru
sampl
inhibit
cell
growth
treat
hek
cell
h
peptid
concentr
correspond
peptid
concentr
dilut
viru
sampl
contain
highest
peptid
concentr
stain
confirm
peptid
interfer
cell
growth
viabil
fig
health
cell
confirm
presenc
multipl
mitot
event
appar
stain
nuclei
morpholog
chang
cell
detach
round
seen
phase
contrast
imag
vlp
whose
inner
core
form
nluc
fuse
ebola
structur
protein
coat
either
marburg
viru
vsv
glycoprotein
treat
increas
concentr
individu
peptid
cation
peptid
abl
effect
releas
enzym
permit
access
substrat
concentr
fig
effect
peptid
turn
camw
hybrid
cecropin
melittin
modifi
replac
amino
acid
tryptophan
residu
improv
proteolyt
stabil
peptid
releas
half
enzymat
activ
concentr
peptid
small
activ
cation
peptid
abl
releas
luciferas
activ
concentr
exceed
noteworthi
observ
moder
virolyt
activ
treatment
maximin
gala
peptid
manifest
neglig
hemolyt
activ
analyz
two
type
vlp
carri
differ
viral
envelop
distinct
virus
vsv
belong
rhabdovirida
famili
marburg
viru
fall
filovirida
observ
signific
differ
lytic
activ
vlp
differ
envelop
protein
maximin
gala
kala
higher
concentr
abl
liber
nluc
particl
coat
vsv
compar
particl
marburg
viru
glycoprotein
differ
neglig
experi
notic
tween
use
vlp
lysi
inhibit
nluc
activ
peptid
mostli
concentr
appar
activ
exceed
attribut
tween
lyse
sampl
test
deterg
found
inhibit
nluc
similar
extent
data
shown
despit
inhibitori
activ
tween
decid
use
order
compar
rel
activ
individu
peptid
relat
common
lytic
compound
interestingli
found
camw
unknown
reason
concentr
exceed
strongli
inhibit
nluc
enzym
activ
result
total
elimin
signal
depict
fig
inhibitori
effect
confirm
cell
lysat
cell
express
nluc
alon
data
shown
order
compar
result
virolyt
assay
conduct
vlp
cytotox
peptid
perform
viabil
test
hek
hela
cell
treat
individu
peptid
concentr
use
previous
fig
viabil
assay
mtt
follow
pattern
hemolyt
assay
except
camw
peptid
peptid
high
hemolyt
activ
show
reduc
cytotox
compar
hecat
kala
anion
peptid
maximin
gala
inconsequenti
inhibitori
activ
growth
hek
hela
cell
melittin
toxic
peptid
cell
line
assay
systemat
compar
sever
assay
commonli
use
determin
lytic
activ
sever
antimicrobi
peptid
compar
newli
design
assay
base
ebolalik
vlp
contain
sensit
luciferas
report
enzym
choic
ebola
viruslik
particl
motiv
eas
vlp
product
increas
load
capac
compar
spheric
virus
despit
fact
vlp
base
ebola
viru
use
safe
requir
special
biosafeti
contain
particl
contain
genet
inform
therefor
replic
repres
biolog
hazard
use
laboratori
regardless
biosafeti
level
exact
mechan
pore
format
cation
peptid
subsequ
membran
lysi
cytotox
still
remain
elus
membran
lysi
initi
attach
peptid
surfac
membran
certain
peptidelipid
ratio
peptid
invad
cell
membran
form
toroid
pore
ladokhin
et
al
shown
pore
form
melittin
reach
size
nm
allow
passag
compound
sever
kda
assum
pore
format
caus
loss
membran
potenti
loss
ion
gradient
incompat
vital
cell
function
howev
propos
mechan
explain
virolyt
properti
peptid
envelop
virus
depend
biochem
gradient
jackman
et
al
propos
lysi
viral
membran
strain
induc
membran
envelop
viru
core
highli
curv
impos
substanti
stress
format
pore
induc
membran
tear
reliev
curvatur
induc
stress
assay
camw
compar
hemolyt
activ
human
rbc
melittin
higher
hemolyt
activ
equin
rbc
data
correspond
result
ji
et
al
camw
mgl
equal
rel
low
lytic
activ
unfortun
author
analyz
hemolyt
activ
peptid
higher
concentr
directli
compar
result
concentr
camw
induc
hemolysi
rbc
melittin
fig
complet
lysi
achiev
concentr
peptid
make
camw
melittin
hemolyt
peptid
assay
avail
literatur
camw
describ
peptid
low
hemolyt
activ
howev
test
perform
sheep
rbc
result
show
human
rbc
lyse
quit
effici
equin
rbc
resist
peptidesmedi
lysi
contradict
uncommon
low
concentr
protegrin
hemolyt
human
mous
rbc
howev
essenti
nonhemolyt
sheep
bovin
rbc
emphas
flaw
use
hemolyt
test
evalu
potenti
lytic
activ
peptid
virus
result
hemolyt
assay
correspond
extend
cytotox
assay
except
camw
peptid
peptid
show
lower
cytotox
activ
compar
melittin
make
potenti
interest
antivir
compound
result
hemolyt
assay
correspond
well
vlp
lytic
assay
anion
peptid
maximin
gala
caus
small
releas
hemoglobin
human
rbc
peptid
show
moder
abil
releas
nluc
ebolalik
vlp
low
hemolyt
activ
maximin
gala
explain
fact
assay
perform
neutral
ph
side
chain
glutam
aspart
acid
deproton
peptid
form
structur
necessari
prerequisit
pore
format
target
membran
interestingli
gala
abl
inhibit
infect
cell
recombin
lentivirus
deliv
gfp
gene
infect
cell
assum
effect
mediat
direct
lysi
viral
membran
disrupt
membran
delay
probabl
happen
viru
intern
endosom
acidif
insid
late
endosom
gala
adopt
conform
virus
normal
intern
receptormedi
endocytosi
sequest
viru
particl
endosom
acidifi
along
endocyt
pathway
declin
ph
activ
envelop
protein
initi
process
fusion
viru
membran
endosom
membran
result
releas
viru
capsid
cell
cytoplasm
howev
gala
peptid
present
endosom
convert
random
coil
amphipath
form
channel
insid
viral
membran
lead
viru
inactiv
altern
peptid
emb
endosom
membran
form
ion
pore
prevent
endosom
acidif
similar
proton
channel
influenza
viru
insuffici
chang
ph
endosom
prevent
viral
envelop
protein
effect
fusion
endosom
membran
releas
viral
cargo
cytoplasm
inhibitori
activ
maximin
minor
compar
gala
specul
reason
one
possibl
might
reflect
total
neg
charg
peptid
maximin
carri
three
aspart
acid
residu
provid
charg
gala
harbor
glutam
acid
residu
reach
net
charg
make
far
neg
therefor
sensit
ph
chang
ph
depend
lysi
vlp
anion
peptid
probabl
use
virolyt
assay
adjust
ph
valu
common
late
endosom
though
studi
effect
ph
system
anoth
reason
use
hemolyt
assay
determin
antivir
properti
newli
discov
design
peptid
erythrocyt
sensit
ph
chang
effect
anion
peptid
reliabl
evalu
hemolysi
assay
detect
virolyt
activ
maximin
gala
enzymat
vlp
compar
low
hemolyt
activ
like
reflect
higher
respons
vlp
toward
membran
disrupt
agent
high
sensit
luciferas
assay
membranolyt
properti
peptid
often
evalu
use
synthet
liposom
despit
difficulti
liposom
prepar
artifici
composit
valuabl
tool
due
easi
use
possibl
devis
rel
simpl
biochem
assay
enzymat
vlp
provid
sever
advantag
liposom
sensit
assay
compar
use
liposom
howev
prepar
particl
encumb
requir
equip
necessari
liposom
prepar
vlp
inher
stabl
aggreg
easili
synthet
liposom
due
fact
deriv
live
cell
membran
composit
much
close
relat
real
virus
vlp
incorpor
specif
viral
envelop
protein
mimick
studi
viru
besid
contain
membran
protein
includ
glycosyl
extracellular
protein
ident
infecti
virus
result
membranolyt
assay
carri
nake
liposom
mislead
mani
protein
present
virus
viruslik
particl
surfac
interfer
peptid
peptid
also
sequest
charg
peptidoglycan
viru
surfac
effect
shield
membran
peptid
respect
result
deriv
use
enzymat
vlp
biolog
relev
compar
data
acquir
use
synthet
liposom
amp
gain
attent
potenti
antivir
compound
alreadi
found
clinic
practic
applic
exampl
melittin
incorpor
microbicid
vagin
gel
prevent
hiv
transmiss
anoth
peptid
low
vagin
epitheli
toxic
antihiv
activ
consid
potenti
compon
virucid
gel
deriv
caerin
result
indic
use
camw
consid
similar
clinic
applic
due
reduc
cytotox
compar
melittin
anoth
interest
candid
gala
peptid
neglig
hemolyt
cytotox
activ
even
concentr
effect
block
viru
entri
concentr
result
demonstr
newli
design
assay
evalu
virolyt
properti
sensit
better
reflect
potenti
peptid
interfer
viral
membran
compar
standard
hemolyt
assay
greatest
advantag
rel
low
cost
vlp
prepar
potenti
highthroughput
screen
assay
accomplish
short
time
compar
test
carri
report
cell
line
use
vlp
provid
flexibl
respect
surfac
particl
ad
versatil
assay
target
specif
viral
epitop
assay
also
use
infecti
viru
particl
allow
use
standard
biosafeti
level
laboratori
assay
avoid
certain
drawback
hemolyt
assay
mainli
fals
posit
result
due
differ
membran
composit
speciesspecif
sensit
given
peptid
among
peptid
analyz
work
modifi
peptid
camw
activ
peptid
virus
vlp
surpass
progenitor
melittin
melittin
deriv
hecat
camw
also
reduc
cytotox
compar
melittin
surprisingli
found
gala
peptid
possess
viru
entri
inhibitori
activ
probabl
relat
adopt
activ
conform
within
endosom
